397 related articles for article (PubMed ID: 20399992)
1. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
[TBL] [Abstract][Full Text] [Related]
2. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
4. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007.
Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L
Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
7. [Treatment patterns in advanced breast cancer with anthracycline and taxanes and their costs in three public hospitals of Mexico].
Silva JA; Gonzalez JF; Bargalló JE; Hernández-Rivera G; Gómez-Roel X; Rangel S; Vargas-Valencia JJ; Martínez-Fonseca J; Donato BM; Juárez-García A
Value Health; 2011; 14(5 Suppl 1):S147-50. PubMed ID: 21839890
[TBL] [Abstract][Full Text] [Related]
8. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
[TBL] [Abstract][Full Text] [Related]
9. [Current trends in pharmacotherapy of breast cancer].
Boér K
Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
11. Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.
Barnett CM
Pharmacotherapy; 2009 Dec; 29(12):1482-90. PubMed ID: 19947807
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
14. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
15. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
16. Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial.
Shiroiwa T; Fukuda T; Shimozuma K; Kuranami M; Suemasu K; Ohashi Y; Watanabe T
Value Health; 2011; 14(5):746-51. PubMed ID: 21839414
[TBL] [Abstract][Full Text] [Related]
17. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G
Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617
[TBL] [Abstract][Full Text] [Related]
18. Other options in the treatment of advanced breast cancer.
Cobleigh MA
Semin Oncol; 2011 Jun; 38 Suppl 2():S11-6. PubMed ID: 21600380
[TBL] [Abstract][Full Text] [Related]
19. First-line chemotherapy for metastatic breast cancer in patients ≥75 years: a retrospective single-centre analysis.
Debled M; Madranges N; Mertens C; Durand M; Brouste V; Brain E; Mauriac L
Crit Rev Oncol Hematol; 2011 Oct; 80(1):171-9. PubMed ID: 21036058
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant taxanes: more to the story.
Gajria D; Seidman A; Dang C
Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S41-9. PubMed ID: 20805064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
